Refuge: Receptive CAR checkpoints

How Refuge is using CRISPR to suppress checkpoint genes in CAR T cells

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety.

CEO Bing Wang told BioCentury that like endogenous T cells, CAR T cell therapies also express checkpoint proteins that can limit their anti-tumor activity.

Wang said Refuge designs its CARs to trigger checkpoint suppression by attaching a protease

Read the full 728 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE